COGNITIVE / DIRECT CATALOG PRICING
PE-22-28
PE-22-28 is a seven-amino-acid peptide designed from blood-degradation products of spadin, a peptide related to the sortilin/propeptide system and studied as a TREK-1 channel inhibitor.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 0
- Catalog class
- Cognitive
- 8 mgPricing by inquiry · AvailableSelect
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
PE-22-28 is a seven-amino-acid peptide designed from blood-degradation products of spadin, a peptide related to the sortilin/propeptide system and studied as a TREK-1 channel inhibitor.
The cognitive classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Cognitive
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- Contact for current availability
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
PE-22-28 is a seven-amino-acid peptide designed from blood-degradation products of spadin, a peptide related to the sortilin/propeptide system and studied as a TREK-1 channel inhibitor.
- Research covered
- The primary study tested PE-22-28 and related analogues in hTREK-1-expressing HEK cells, mouse cortical-neuron cultures, and mouse behavioral models. It reported channel inhibition, stability measurements, and cellular or behavioral endpoints.
- Important limit
- The evidence is in vitro and in mice; no human clinical evidence was identified. Results for modified analogues cannot automatically be assigned to the exact unmodified catalog peptide, whose identity also requires analytical confirmation.
- Authoritative sources
FACTUAL FAQ
PE-22-28 catalog questions
What formats are currently listed?
8 mg. Current price and stock state appear above.
What did researchers study?
The primary study tested PE-22-28 and related analogues in hTREK-1-expressing HEK cells, mouse cortical-neuron cultures, and mouse behavioral models. It reported channel inhibition, stability measurements, and cellular or behavioral endpoints.
What is the most important evidence limit?
The evidence is in vitro and in mice; no human clinical evidence was identified. Results for modified analogues cannot automatically be assigned to the exact unmodified catalog peptide, whose identity also requires analytical confirmation.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →
